Folotyn for Non-Hodgkin's Lymphoma Jacksonville FL

The drug Folotyn (pralatrexate) has been approved to treat Peripheral T-cell Lymphoma (PTCL), an often aggressive form of non-Hodgkin's lymphoma, the U.S. Food and Drug Administration said Friday. The drug, given accelerated approval because it treats an unmet medical need, was sanctioned for people whose disease has returned or hasn't responded to other types of chemotherapy, the agency said in a news release.

Manisha Makker Bansal
(904) 390-3600
807 Childrens Way
Jacksonville, FL
Specialty
Pediatric Hematology-Oncology

Data Provided by:
Cynthia A Gauger, MD
(904) 390-3793
807 Childrens Way
Jacksonville, FL
Specialties
Oncology (Cancer)
Gender
Female
Education
Medical School: Univ Of Tx Southwestern Med Ctr At Dallas, Med Sch, Dallas Tx 75235
Graduation Year: 1993

Data Provided by:
Jaswant Sinh Jadeja, MD
(904) 739-7779
4480 Worth Dr S
Jacksonville, FL
Specialties
Oncology (Cancer)
Gender
Male
Education
Medical School: Grant Med Coll, Univ Of Bombay, Bombay, Maharashtra, India
Graduation Year: 1972

Data Provided by:
Leann Lessl Fox, MD
(904) 390-3674
807 Childrens Way
Jacksonville, FL
Specialties
Oncology (Cancer)
Gender
Female
Education
Medical School: Univ Of South Al Coll Of Med, Mobile Al 36688
Graduation Year: 1988

Data Provided by:
Joseph Mignone
(904) 493-5100
1235 San Marco Blvd
Jacksonville, FL
Specialty
Internal Medicine, Hematology / Oncology

Data Provided by:
Neil Abramson
(904) 493-5100
1235 San Marco Blvd
Jacksonville, FL
Specialty
Hematology / Oncology

Data Provided by:
Suneel Laxman Mahajan, MD
(904) 739-7779
5742 Burth Rd
Jacksonville, FL
Specialties
Oncology (Cancer), Hematology-Internal Medicine
Gender
Male
Education
Medical School: Bj Med Coll, Univ Of Pune, Pune, Maharashtra, India
Graduation Year: 1974

Data Provided by:
Scott Mark Bradfield, MD
807 Childrens Way
Jacksonville, FL
Specialties
Oncology (Cancer)
Gender
Male
Education
Medical School: Univ Of South Fl Coll Of Med, Tampa Fl 33612
Graduation Year: 1997

Data Provided by:
Douglas William Johnson
(904) 202-7020
1235 San Marco Blvd
Jacksonville, FL
Specialty
Radiation Oncology

Data Provided by:
Cynthia A Gauger
(904) 390-3789
807 Childrens Way
Jacksonville, FL
Specialty
Pediatric Hematology-Oncology

Data Provided by:
Data Provided by:

Folotyn for Non-Hodgkin's Lymphoma

Provided By:

FRIDAY, Sept. 25 (HealthDay News) -- The drug Folotyn (pralatrexate) has been approved to treat Peripheral T-cell Lymphoma (PTCL), an often aggressive form of non-Hodgkin's lymphoma, the U.S. Food and Drug Administration said Friday.

The drug, given accelerated approval because it treats an unmet medical need, was sanctioned for people whose disease has returned or hasn't responded to other types of chemotherapy, the agency said in a news release.

PTCL strikes fewer than 9,500 people each year in the United States, the FDA said. The disease affects a type of white blood cell, called a T-cell, involved in the body's disease-fighting immune system.

Approval of Folotyn was based on clinical data showing it reduced tumor size in 27 percent of 109 people with PTCL who were studied. The most common adverse reactions included sores of the lips, mouth and digestive tract, low white blood cell counts, fever, nausea and fatigue.

Since the drug can harm a fetus, women taking Folotyn should avoid becoming pregnant, the FDA said. Anyone taking the drug should also take folate and vitamin B12 supplements to help reduce irritation of the mucous membranes.

Folotyn is produced by Colorado-based Allos Therapeutics, which is required to conduct additional studies of tumor shrinkage and life expectancy, the agency said.

More information

The FDA has more about this drug.

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com

Mailing Address:
Jacksonville Magazine
1261 King St.
Jacksonville, FL 32204
TEL: (904) 389-3622
FAX: (904) 389-3628
E-mail: mail@jacksonvillemag.com